AbbVie, Bristol-Myers Squibb, Genentech, Janssen and Merck & Co. have all advanced anti-tau candidates into Phase I trials in the hunt for drugs that can modify the course of Alzheimer disease.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
2D versus 3D human induced pluripotent stem cell-derived cultures for neurodegenerative disease modelling
Molecular Neurodegeneration Open Access 22 May 2018
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Rights and permissions
About this article
Cite this article
Mullard, A. Pharma pumps up anti-tau Alzheimer pipeline despite first Phase III failure. Nat Rev Drug Discov 15, 591–592 (2016). https://doi.org/10.1038/nrd.2016.176
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd.2016.176
This article is cited by
-
2D versus 3D human induced pluripotent stem cell-derived cultures for neurodegenerative disease modelling
Molecular Neurodegeneration (2018)
-
Clinical Research on Alzheimer’s Disease: Progress and Perspectives
Neuroscience Bulletin (2018)
-
Tau-based therapies in neurodegeneration: opportunities and challenges
Nature Reviews Drug Discovery (2017)
